Ann: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting, page-108

The question I ask…

Would Danege Li be presenting if there had been a data cut completed showing further promising data?

We are 5 mths on from the first VAXINA results and in that time trial participants been dosed escalated, and completed scans to show the effectiveness of the treatment.

IMU would be in close contact with the trial organisers and be privy to the current status of patients and their scan results.

Was the feedback from the trial organisers, no further improvement and IMU decided not to do a further data cut, which would explain why there is no further data to be presented at the AACR?

Would this explain why YF or LC have decided not to present?

That’s the question I ask?

There are a lot of emotional investors on these IMU forums that should be wary of spin by both posters and IMU announcements.

DYOR, my opinion’s only